An Expanded Access Trial for Cancer Patients with Specific Mutations
An investigational drug is being used in an expanded access trial for advanced pancreatic and other cancer patients with specific genetic changes.
AACR Virtual Special Conference on Pancreatic Cancer: Day One Highlights
Let's Win and the Lustgarten Foundation present highlights of Day One of the AACR Virtual Special Conference on Pancreatic Cancer.
GENERATE Trial Expands Eligibility
Dr. Sapna Syngal explains the expanded eligibility standards for the GENERATE Study for genetic testing of pancreatic cancer patients and relatives.
Looking Back at the Year in Research: 2019
The research highlights of 2019 include: approval of a PARP inhibitor, artificial intelligence to diagnose pancreatic cysts, and updated radiation guidelines.
Tumor RNA Testing Leads to Treatment with a New Drug
When treatment stopped working for Adam Deal, genetic testing of his tumor RNA found a mutation that made him eligable to try a new drug.
Studying One Family’s Mutations May Change Pancreatic Cancer Treatment and Prevention
Dr. Sahar Nissim is studying the genetic mutations in one family predisposed to pancreatic cancer, to find new ways to combat the disease.
Searching for Potential Pancreatic Cancer Blood Biomarkers
Researchers are using blood samples to follow people considered at-risk for developing pancreatic cancer in a trial looking for early detection biomarkers.
Questions to Ask Before You Begin Chemotherapy
Do you want to better understand your pancreatic cancer treatment? Dr. Andrew Hendifer outlines important questions to ask before starting chemotherapy.
GENERATE Study Aims to Improve Genetic Testing and Prevention for Pancreatic Cancer
Dr. Sapna Syngal outlines the GENERATE study, which aims to help families with a risk for pancreatic cancer by providing genetic testing.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.